| Mark Fishman | |
|---|---|
| Residence | United States |
| Fields | Medicine, Cardiology |
| Institutions | Novartis Institutes of BioMedical Research, Massachusetts General Hospital, Harvard Medical School |
| Alma mater | Yale College, Harvard Medical School |
| Known for | pioneering Zebrafish research in cardiology |
| Notable awards | Institute of Medicine member, Fellow of the American Academy of Arts and Sciences |
Mark Fishman is a noted researcher and clinician in cardiology and the current President of the Novartis Institutes of BioMedical Research (NIBR),[1] the main research arm of Novartis Pharmaceuticals with over 5,000 employees and a 2008 budget of $5.7B.[2]
Fishman was appointed President of the newly-founded Novartis Institutes of BioMedical Research in 2002 to implement a new strategy in Novartis' global drug discovery effort.[3] He is the author of over 100 publications[4] and known for pioneering research using the zebrafish as a means of visualizing the development of the circulatory system and as a model for human disease.[5][6][7]
Contents |
He was previously a Professor of Medicine at Harvard Medical School, Chief of Cardiology at Massachusetts General Hospital, and director of the Cardiovascular Research Center at Massachusetts General Hospital. He is a fellow of the National Academy of Arts and Sciences and a member of the National Academy of Sciences, Institute of Medicine.[8]